NATURALISTA CAMPANO
ISSN: 1827-7160
Volume 28 Issue 1, 2024

Deciphering the Puzzle: A Thorough Examination of Microsphere Optimization through Factorial Design Methodology, Unveiling Novel Strategies and Promising Directions

Kusuma KC[1], Subhash PG[2], Hindustan Abdul Ahad[3*], Shreya J Poojari[4], Abhishek J[5], Ashritha[6]

[1,2,3,4,5,6]Department of Pharmaceutics, RR College of Pharmacy, Chikkabanavara, Bangalore-560090, Karnataka, India

Corresponding author: E-Mail: abdulhindustan@gmail.com

Abstract: This study aims to provide a comprehensive overview of using factorial design as an optimization strategy for the preparation of microspheres, enhancing their drug delivery efficacy and therapeutic potential. Factorial design, employed as a statistical tool to investigate multiple variables simultaneously, systematically varied factors such as polymer type, solvent composition, stirring rate, and drug-to-polymer ratio. Experimental design involved careful selection of factors and levels to explore individual and interactive effects on microsphere properties, with data analysis performed using statistical techniques like analysis of variance (ANOVA). Results showed that factorial design efficiently identified critical factors influencing characteristics such as particle size, morphology, drug encapsulation efficiency, and drug release profile, offering advantages over traditional methods, including reduced experimentation time, improved understanding of variable interactions, and enhanced optimization robustness. Ultimately, factorial design proves to be a systematic and efficient approach for optimizing microsphere preparation in pharmaceutical research, facilitating the development of microspheres tailored to specific therapeutic requirements and thereby enhancing drug delivery efficacy while minimizing side effects.

Keywords: Controlled drug delivery, Factorial design, Microspheres, Optimization, Pharmaceutical research

1. Introduction

Microencapsulation technology, introduced in the 1940s and 1960s, revolutionized drug delivery methods. The 1980s marked significant progress with the development of polymer and membrane technologies, aiming for more advanced systems. Bioactive molecules can now be attached to carriers such as liposomes, bioerodable polymers, implants, monoclonal antibodies, nanoparticles, and microspheres for precise targeting and site-specific delivery. Microspheres, spherical particles typically between 1 μm and 1000 μm in size, are made from

biodegradable synthetic polymers or proteins, ideally under 200 μm in diameter, and are characterized by their free-flowing powder form.
Extensive research on microspheres has demonstrated their potential in drug delivery systems, showing they can protect sensitive macromolecules from acidic and enzymatic degradation while enabling targeted and controlled drug release. Various drug carriers, including soluble polymers, cells, cell ghosts, lipoproteins, liposomes, microcapsules, and microparticles from natural and synthetic biodegradable polymers, can be conjugated with specific antibodies to target distinct regions. These carriers can be designed to be pH or temperature-sensitive, slowly degradable, and highly targeted.
Microspheres, roughly spherical solid particles ranging from 1 to 1000 μm, can also appear as microcrystalline particles or pharmaceuticals dispersed in solutions. Often, the terms microspheres and microcapsules are used interchangeably. Drugs administered through the gastrointestinal tract (GIT) with a short half-life are quickly eliminated from the bloodstream. To address this, oral sustained or controlled release (CR) medications have been developed, releasing the drug gradually into the GIT and maintaining consistent plasma drug levels over an extended period [1].

Advantages
The merits of microspheres are as follows [2]:
- A decrease in stomach discomfort.
- Boost bioavailability
- Extended half-life in biology.
- Lowers toxicity and dosage.
- Offer a prolonged and consanguineous therapeutic impact.
- Reducing the size of particles to increase poorly soluble medication solubility.
- They decreased the drug's concentration at a location other than the target organ or tissue.
- They offer protection for unstable medicine both before and after delivery.

Disadvantages
The demerits of microspheres are as follows[2]:
- Because controlled-release formulations often have larger drug loads, any compromise in the dosage form's release properties might result in dosage dumping, treatment failure, and even toxicity.
- If the carrier has a harmful impact, it might be challenging to fully eliminate it from the body after injection.
- Low drug loading (up to 50%) for parents with controlled release.
- Microspheres delivered by parents may interact or combine to create complexes with the blood component.
- These dosage forms shouldn't be eaten or crushed.
- Variations in the rate of release between doses.

2. Methods of Preparation

Single emulsion technique
Microparticulate carriers derived from naturally occurring polymers, sourced from proteins and dietary elements, are pivotal in diverse fields like drug delivery and food science. Initially, these polymers are dispersed or dissolved in an aqueous medium to ensure uniform distribution.

Subsequently, the aqueous mixture is introduced into a non-aqueous, oil-based medium, often forming emulsions where polymer-containing droplets are dispersed within the oil phase. The crucial step of stabilizing these droplets and forming solid microparticles involves cross-linking. Cross-linking can be achieved through heat application or chemical agents like formaldehyde or glutaraldehyde, which induce covalent bonds between polymer chains, creating a stable network. The choice of cross-linking method depends on factors such as polymer characteristics and desired microparticle properties. Chemical cross-linking offers precise control over properties but requires careful handling due to the use of potentially hazardous chemicals. In essence, the process involves dispersing polymers, creating emulsions, and cross-linking to produce stable microparticles for varied applications.[3].

Double emulsion technique

The double emulsion method of microsphere synthesis stands as an ideal choice for encapsulating water-soluble medications, peptides, proteins, and vaccines. This technique involves the creation of a double water-in-oil-in-water (w/o/w) emulsion or multiple emulsions. It offers versatility by accommodating both synthetic and natural polymers. In this process, an aqueous protein solution containing the active ingredients is dispersed within a lipophilic organic continuous phase. This arrangement facilitates the encapsulation of the active components within the protein solution, ensuring their protection and controlled release. The method's adaptability to various types of polymers and its ability to encapsulate sensitive bioactive compounds make it a valuable approach in pharmaceutical and biomedical applications [4]. The protein present in the continuous phase is eventually wrapped by the polymer solution, which is often composed of the scattered aqueous phase. The aqueous polyvinyl alcohol solution (PVA) is then mixed with the primary emulsion and homogenized, or sonicated. This results in the creation of a double emulsion. Next, the solvent needs to be removed from the emulsion by solvent evaporation or solvent extraction.

Solvent evaporation technique

The process of creating microparticles using this technique incorporates the extraction of the organic phase using a suitable solvent. Water, being a miscible organic solvent, is often utilized for this purpose, facilitating the removal of the organic phase. This extraction step is crucial as it effectively eliminates the organic solvent, thereby reducing the time required for microparticle formation. One approach within this procedure involves the direct addition of the medication into the organic phase. The efficiency of elimination is influenced by various factors, including the volume of the emulsion, the solubility profile of the polymer in water, the quantity of solvent used, the temperature of the water, and other pertinent variables. Careful consideration and optimization of these parameters are essential to ensure the successful fabrication of microparticles with desired characteristics and functionalities [5].

Method of phase separation and coacervation

The primary objective of this process is to modulate the solubility of the polymer during the initial stages to drive the formation of a distinct phase known as coacervates, enriched in polymers. By employing this technique, an incompatible polymer is blended with a solution containing the drug-loaded polymer. The first polymer serves to absorb the drug particles, inducing phase separation within the solution. Subsequently, the addition of a non-solvent leads to the solidification of the polymer. This method finds application in the production of polylactic acid (PLA) microspheres, particularly when the polymer is incompatible with the

drug, as in the case of butadiene. Factors such as the dispersion of the polymer film, particle size, and agglomeration of the resultant particles are influenced by the rate of coacervate synthesis, making precise control of process variables crucial. To prevent agglomeration, it is imperative to vigorously agitate the suspended material using a stirrer operating at an appropriate speed. Failure to do so may result in the formation of agglomerates comprising polymerized globules, ultimately affecting the quality and uniformity of the microspheres produced[6].

Spray drying

The closed, one-step system approach offers a versatile and efficient method for producing microspheres from a diverse range of materials, even those sensitive to heat. In this process, both the polymer coating and the medication components are either suspended or dissolved within a coacervate or emulsion system. Typically, a solvent like methylene chloride is used to dissolve the drug and polymer. For instance, in the case of polylactide microspheres, they can be formed directly in the polymer solution or dissolved in a suitable solvent, whether aqueous or not. The size of the microspheres generated is influenced by several key factors. These include the nozzle size, the temperature maintained in both the drying and gathering chambers, the rate at which the drug solution is supplied based on the polymer, and the dimensions within the two chambers. Precise control and optimization of these variables are crucial to achieve the desired size and properties of the microspheres. This meticulous approach ensures the adaptability of the technique to various pharmaceutical and biomedical applications, making it a valuable tool in drug delivery and related fields.

Hot melt and wax coating method

The process involves using melted wax to dissolve or disperse the main ingredients, encapsulating them within the wax matrix. This is achieved by blending a waxy paste or mixture, such as frozen liquid paraffin, vigorously with cold water. The blending process typically takes at least an hour, during which the mixture is intensely agitated. Once the blending is complete, the external layer, consisting of liquid paraffin, is decanted, leaving behind the microspheres encased within the wax matrix. To further refine the microspheres, they are submerged in a non-miscible solvent and allowed to dry in dry air. Suitable surface ingredients for enhancing the properties of the microspheres include beeswax and carnauba wax. It is often advantageous to combine these two waxes to achieve the desired effects, such as improved stability or controlled release of the encapsulated ingredients. This process enables the production of microspheres with tailored properties for various applications in pharmaceuticals, cosmetics, and other industries.

Ionic gelation technique

Ionotropic gelation is a technique that exploits the ability of polyelectrolytes to form hydrogel beads, known as gelispheres, through cross-linking in the presence of counter ions. Gelispheres are circular, hydrophilic, cross-linked polymeric agents that exhibit significant gelation and thickening in simulated biological fluids. They also enable controlled drug release through polymer relaxation. The process involves pouring a drug-filled polymeric solution into an aqueous solution containing polyvalent cations. As the cations interact with the hydrophilic compounds in the solution, they ionically crosslink the moieties, forming a three-dimensional lattice structure. This crosslinking process creates the hydrogel beads, encapsulating the drug within. Additionally, biomolecules can be incorporated into these gelispheres under mild

conditions to maintain their three-dimensional shape. This feature makes ionotropic gelation a versatile technique for the controlled release of drugs and biomolecules in various biomedical applications.

Evaluation

Percentage Yield: This metric assesses the efficiency of the microsphere production process by comparing the actual yield (measured by the mass of the collected microspheres) to the theoretical yield (expected mass based on the starting materials used). It helps in evaluating the effectiveness of the manufacturing process and identifying any potential losses or inefficiencies.

Optical Microscopy: Optical microscopy is used to examine the morphology and size distribution of the microspheres. By observing microspheres under a microscope, researchers can assess their shape, size, and uniformity. This information is crucial for understanding how the manufacturing process affects the physical characteristics of the microspheres and ensuring consistency in size and shape, which can impact their performance in drug delivery applications.

Scanning Electron Microscopy (SEM): SEM provides high-resolution imaging of the microsphere surface, allowing for detailed analysis of their structure, morphology, and surface properties at a micro to nanoscale level. Additionally, Energy Dispersive X-ray Analysis (EDXA) helps in identifying the elemental composition of the microspheres, providing insights into their chemical composition and potential impurities.

Flow Characteristics Analysis: Flow properties such as Carr's compressibility index, Hausner's ratio, and angle of repose are crucial for assessing the flow behavior of microspheres. These properties influence how the microspheres flow, pack, and disperse during manufacturing processes like tableting, capsule filling, or powder blending. Understanding flow characteristics is essential for optimizing formulation and manufacturing processes to ensure uniformity and consistency in drug delivery systems.

Thermodynamic Evaluation: Thermal analysis techniques like Differential Scanning Calorimetry (DSC) and Thermogravimetric Analysis (TGA) provide information on the thermal behavior, phase transitions, and stability of microspheres under various temperature and environmental conditions. This helps in understanding the physical and chemical properties of the microspheres, including their melting point, glass transition temperature, and degradation behavior, which are critical for ensuring their stability and performance over time.

Drug Content Determination: This method quantifies the amount of drug present in the microspheres, providing insights into the efficiency of drug loading during the formulation process. By accurately determining the drug content, researchers can assess the formulation's effectiveness, optimize drug loading procedures, and ensure consistent dosing in drug delivery applications.

Entrapment Efficiency: Entrapment efficiency calculates the percentage of the drug effectively trapped within the microspheres, providing information on the efficacy of the encapsulation process. It helps in evaluating the formulation's ability to retain the drug within

the microspheres and assesses the overall drug loading capacity, which is essential for controlling drug release kinetics and maximizing therapeutic efficacy in drug delivery systems.

QbD

Quality-by-Design (QbD) in pharmaceutical development emphasizes integrating quality into product design and manufacturing processes. It relies on understanding the relationship between product performance, attributes, and processes. Formulations are tailored based on predefined product specifications derived from quality control testing requirements, ensuring that the product meets critical quality attributes (CQAs) for approval in commerce. QbD employs systematic multivariate experiments, often utilizing Process Analytical Technology (PAT), to identify critical process parameters (CPPs) and CQAs through risk assessments. By monitoring and controlling these parameters throughout manufacturing, consistent product quality is ensured. While end-product testing verifies quality, it cannot substitute for process control or consistency. QbD aims to proactively design robust processes that consistently produce safe, effective, and high-quality pharmaceutical products, minimizing regulatory issues and financial impacts associated with batch rejection or reprocessing[7]. Product lifecycle management facilitates ongoing monitoring and enhancement to maintain quality standards. By integrating these elements, QbD ensures the production of safe, effective pharmaceuticals while minimizing risks and variability throughout the product lifecycle[8]. A product must have TPQP, or performance-based quality characteristics, to fulfil TPP. TPP is translated into quantitative testing by TPQP, including assay, impurities, content homogeneity, dissolution, stability, and bioequivalence [9].

Design and development of product

In pharmaceutical development, the essential characteristics of a product are determined by the physicochemical and pharmacological properties of the active pharmaceutical ingredient (API). The goal of a Quality-by-Design (QbD)-based product development program is to meet patient needs and identify the characteristics necessary for the pharmacological product to achieve the intended therapeutic response. To attain these predetermined goals, product development must be systematic, scientific, and risk-based. The inclusion of experiential knowledge adds value to this comprehensive approach at various stages. A thorough understanding of the product and its production process facilitates the identification of Critical Quality Attributes (CQAs) that must be managed to consistently produce the desired output. This methodical and informed approach ensures the development of safe, effective, and high-quality pharmaceutical products [10].

Design of experiments

Experiment design is a powerful tool for systematically planning and executing experiments to generate accurate and coherent data. However, it's crucial to understand that experiment design works hand in hand with experience, competence, and intellect rather than replacing them. While experiment design provides a structured framework for understanding the relationship between various factors and outcomes, successful experimentation also relies on the researcher's expertise, judgment, and ability to interpret results within the broader context of their knowledge and experience. Experiment design helps researchers identify and control variables, optimize conditions, and draw meaningful conclusions from data. Yet, it's the insights and expertise of skilled practitioners that truly maximize the effectiveness of

experiment design. Therefore, a combination of both is essential for achieving reliable and insightful results in scientific research and experimentation[11].

Common experimental designs

A certain amount of reasoning or experience-based knowledge should be used to determine which aspects are dependent and independent. Incorporating all pertinent variables is crucial. Impractical and unattainable levels should not be incorporated into the design; instead, reasonable high and low values should be selected for the factors[9].

- **Completely randomized designs:** In this case the response variable derived only from the various values of a primary component, without accounting for any additional factors.
- **Randomized block design:** In this case, there will only be one main component, and blocking is utilized to reduce the impact of uncontrollable but unimportant elements.
- **Full factorial designs:** Every level of each element appears alongside every level of every other factor in this design. The variables will be at high or low levels. The number of experimental runs needed for "n" number of independent factors with two levels is equal to 2^n.
- **Fractional factorial designs:** Here, rather than doing every run as in full factorial design, a carefully selected subset of the runs is chosen. As the number of components rises, full factorial design can easily grow to a very larger design.
- **Plackett–Burman designs:** These designs are considered highly efficient when the variable's primary impacts are the only ones that matter. Their number for the trial run is a multiple of four. A minimum number of runs is sufficient to examine a very large number of variables.
- **Response surface designs:** Process behavior can be fully described by a quadratic or cubic model. The existence of quadratic and perhaps cubic components in the response is what causes the curvature in the response surface. The pharmaceutical sector always finds that quadratic models are adequate. When more than four components are present, three-level factorial designs may fit a quadratic equation but need a significant number of runs. In contrast, two-level factorial designs cannot fit a quadratic equation. A second-order model is typically utilized to calculate the response when a first-order model is insufficient and the experiment is near the optimal response zone. Special designs fit the second-order model to the response with a minimum number of runs to analyze response surfaces. Box-Wilson central composite designs (CCD) and Box-Behenken designs (BBD) are the two types of classical quadratic designs.

A second-order (quadratic) model for the response variable is constructed using a CCD. The findings are obtained by the use of linear regression in the design. For the design, the factor levels are often coded. These are fractional factorial or two-level complete factorial designs. Several center points and other selected runs enhance the designs. They make it possible to find every regression parameter required to match a response to a second-order model. The axial points, also known as star points, are separated from the center point by a symbol, "α." In a CCD, there will be twice as many axial points as independent variables. A CCD can be face-centered (requiring three levels of each factor), circumscribed (requiring five levels of each factor and having circular, spherical, or hyperspherical symmetry), or inscribed (a scaled-down circumscribed CCD with each factor level of the design divided by α to generate this design). Any design should aim for rotatability, which provides equivalent estimating precision in all directions. If a CCD provides consistent variance of the calculated factors corresponding to

every new observation point at the same distance from the center point, then the CCD is said to be rotatable.
BBD is extensively used to fit second-order models to the response. These designs are for three-level variables. Two-level factorial designs and unfinished block designs are used to create the design. These patterns are almost rotatable. One benefit of BBD is that they only need three tiers. It also has an advantage in that there are no runs at the corner points and no runs when all factors are at the +1 or −1 levels. Corner point runs can occasionally be costly or difficult. However, this design's capacity to block orthogonally is restricted when compared to CCD. A graphical method for displaying a 3D surface in a two-dimensional format is called a contour plot. Plotting constant z-slices, often known as contours, on a two-dimensional format yields it. An alternative to a 3D surface plot is a contour plot. The lines show the iso-response values, while the vertical and horizontal axes show the independent components. In the part that describes design space, figures are used to demonstrate the response surface and contour plots.
Three-level full factorial designs: For every aspect, three tiers are taken into account here. Three times the number of independent elements under consideration, n, equals the number of experimental runs. Level codes in this case are -1, 0, and +1. In contrast to the two-level designs, a third level facilitates the investigation of the quadratic connection between each element and the answer[9].

Multivariate tools for design, data acquisition, and analysis
Scientific knowledge of multifactorial interactions in pharmaceutical development is obtained through the application of information management systems and multivariate mathematical approaches. These approaches include response surface methods, process modeling, pattern recognition tools, and experiment design. By utilizing statistical analysis, researchers can assess the reliability and applicability of model predictions. When implemented effectively, these strategies allow for the identification and evaluation of variables related to both the process and product, facilitating informed decision-making and optimization of pharmaceutical processes[12].

Process analyzers
Recent years have witnessed significant advancements in process analyzer technology, revolutionizing the acquisition of data on the chemical, physical, and biological properties of materials in pharmaceutical manufacturing. These advancements encompass at-line, on-line, and in-line measurements, offering non-destructive methods for assessing various parameters. Modern process analyzers provide access to a wealth of data, enabling real-time control and quality assurance throughout the manufacturing process. This enhanced capability empowers pharmaceutical manufacturers to monitor and adjust processes promptly, ensuring product quality and consistency while optimizing efficiency and resource utilization[13]. It evaluates the effectiveness of process analyzers in measuring significant attributes as well[14].

Continuous improvement and knowledge management tools
Throughout a product's life cycle, data may be collected and analyzed, and the findings applied to continuous process and product improvement. PAT encourages a risk-based manufacturing strategy, which can help risk-based innovation and policy decisions. PAT also supports an integrated systems approach and real-time release[15].

Table 1: past work done on microspheres using factorial design

Drug	Design	Independent variables	Dependent variables	References
Aceclofenac	Plackett Burman design	Ethyl cellulose (EC) (X_1), rpm (X_2), and continuous phase volume (X_3)	% EE (Y_1) and PS (Y_2)	[16]
Acetazolamide	Box Behnken design (BBD)	Drug: polymer ratio (X_1), surfactant concentration (X_2), and stirring rate (rpm) (X_3)	%EE (Y_1), Q_{6h} (Y_2), and PS(Y_3)	[17]
Acyclovir	3^2 full factorial design (FFD)	EC (X_1), and carbopol 940 (X_2)	EE (Y_1), $Q_{1\,h}$ (Y_2), $t_{90\%}$ (Y_3), and mucoadhesive strength (Y_4)	[18]
Acyclovir	3^2 FFD	Polymer ratio (X_1), and feed flow rate (X_2)	% Yield (Y_1), and EE (Y_2)	[19]
Amoxicillin	3^2 FFD	Polymer (X_1) , Emulsifying agent (X_2), and rpm (X_3)	% EE (Y_1), and PS (Y_2)	[20]
Carvedilol	3^2 FFD	Drug-to-polymer ratio (X_1), and rpm (X_2)	PS (Y_1), EE (Y_2), t_{50} (Y_3), % Drug release after 5h(Q_{5h}) (Y_4), and Q_{12h} (Y_5)	[21]
Cefpodoxime Proxetil	3^2 FFD	rpm (X_1) and ES100 (X_2)	% drug release (Y_1), EE(Y_2), and PS (Y_3)	[22]
Clotrimazole	3^2 BBD	Drug: polymer ratio (X_1), surfactant concentration (X_2), and rpm (X_3)	Mean particle size (PS) (Y_1), and entrapment efficiency (EE) (Y_2)	[23]
Diclofenac Sodium	3^2 BBD	Chitosan (X_1), tripolyphosphate (X_2), and cross-linking time (X_3)	PS(Y_1) and EE(Y_2)	[24]
Diltiazem hydrochloride	2^3 FFD	Polycarbonate (X_1) and rpm (X_2)	%drug release(Y_1), and %EE (Y_2)	[25]
Esomeprazole	3^2 FFD	Eudragit L(X_1) and stirring speed (X_2)	Drug Release (Y_1), and EE (Y_2)	[26]
Ibuprofen	2^3 FFD	Sodium alginate (X_1), magnesium stearate (X_2), and calcium chloride (X_3)	Release profile (Y_1)	[27]
Ivabradine HCl	3^2 FFD	Polymer (X_1) and rpm (X_2)	% drug loading (Y_1), PS (Y_2), and % CDR (Y_3)	[28]
Metoprolol tartrate	2^3FFD	EC (X_1), rpm (X_2), and different volumes of continuous phase (X_3)	% EE (Y_1),and PS (Y_2)	[16]

Nicorandil	3^2 FFD	drug:polymer ratio (X_1), and volume of Gallic acid (X_2)	% EE(Y_1), PS (Y_2), and Q_{8h} (Y_3)	[29]
Nifedipine	3^2 FFD	EC (X_1), and carbopol 934P(X_2)	% EE (Y_1), % CDR at 1h (Y_2), $t_{90\%}$ (Y_3), and % mucoadhesion (Y_4)	[30]
Nifedipine	3^2BBD	Polymer (X_1), rpm (X_2), and glutaraldehyde (X_3)	PS(Y_1), EE (Y_2), and flow assets (Y_3)	[31]
Quetiapine fumarate	3^2BBD	EC (X_1), type of HPMC (X_2), concentration of HPMC (X_3), chitosan (X_4), and rpm (X_5)	PS (Y_1), EE (Y_2), Q_{24h} (Y_3), and % mucoadhesion (Y_4)	[13]
Quetiapine fumarate	3^2 FFD	Sodium lauryl sulphate (X_1) and drug: polymer ratio (X_2)	% yield (Y_1), % EE (Y_2), PS (Y_3),and % *in-vitro* CDR at 10h (Y_4)	[32]
Rasagiline mesylate	Central composite design(CCD)	Polymer (X_1) and rpm (X_2)	%EE (Y_1), PS (Y_2),and %CDR (Y_3)	[33]
Selegiline hydrochloride	CCD	Karaya gum concentration (X_1), and rpm (X_2)	%CDR (Y_1), % EE (Y_2), and PS(Y_3)	[34]
Sitagliptin Phosphate Monohydrate	3^2 FFD	Poly lactic co glycolic acid (X_1), and feed flow rate (X_2)	PS (Y_1),and % release of drugs (Y_2)	[29]
Stavudine	3^2FFD	Polymer-to-drug ratio (X_1) and rpm (X_2)	EE (Y_1), PS (Y_2), and time to 80% drug release (Y_3)	[35]
Terbinafine	3^2BBD	Poly vinyl alcohol (X_1), Dichloromethane (X_2), and rpm (X_3)	EE (Y_1) and PS (Y_2)	[36]

3. Conclusion

In conclusion, the adoption of factorial design in the fabrication of microspheres for controlled drug delivery represents a significant stride in pharmaceutical research. By methodically investigating the impacts of various formulation variables on microsphere characteristics, factorial design facilitates the fine-tuning of crucial parameters such as particle size, morphology, drug encapsulation efficiency, and drug release kinetics. Its systematic and efficient approach not only streamlines experimentation but also deepens our comprehension of factor interactions, fostering the development of more resilient and efficacious drug delivery platforms. Ultimately, the integration of factorial design methodology holds great promise for

the rational design and refinement of microsphere-based drug delivery systems, offering potential enhancements in therapeutic efficacy and patient care.

4. References

1. Li Q, Chang B, Dong H, Liu X. Functional microspheres for tissue regeneration. Bioactive Materials 2023;25:485-99.
2. Ahad HA, Sreenivasulu R, Mallapu Rani E, Reddy BV. Preparation and evaluation of famotidine high density gastro retentive microspheres with synthetic and natural polymers. Journal of Pharmaceutical Education & Research 2011;2.
3. Mundarinti SHB, Ahad HA. Impact of Pistacia lentiscus plant gum on particle size and swelling index in central composite designed amoxycillin trihydrate mucoadhesive microspheres. Indian Journal of Pharmaceutical Education and Research 2023;57:763-72.
4. Babu GN, Muthukaruppan M, Ahad HA. Impact of Azadirachta indica Fruit Mucilage on particle size and swelling index in Central Composite Designed Acyclovir mucoadhesive microspheres. Baghdad Science Journal 2023;20:0425-.
5. Mundarinti S, Ahad HA. Past decade attempts on gastro retentive microspheres using factorial design: A comprehensive literature. Int J Pharm Phytopharmacol Res 2021;11:24-30.
6. Babu GN, Muthukarupan M, Ahad HA. Neem fruit mucilage impact on acyclovir release at different intervals: A central composite design screening. Int J Pharm Res Allied Sci 2021;10:131-41.
7. Kumar LS, Ahad HA. Quality by Design based Quercetin Hydrate Nanoemulsions for Enhanced Solubility by Reducing Particle Size. Ind J Pharm Edu Res 2023;57:965-70.
8. Abdul AH, Bala AG, Chintaginjala H, Manchikanti SP, Kamsali AK, Dasari RRD. Equator assessment of nanoparticles using the design-expert software. International Journal of Pharmaceutical Sciences and Nanotechnology (IJPSN) 2020;13:4766-72.
9. Hales D, Vlase L, Porav SA, Bodoki A, Barbu-Tudoran L, Achim M, et al. A quality by design (QbD) study on enoxaparin sodium loaded polymeric microspheres for colon-specific delivery. European Journal of pharmaceutical sciences 2017;100:249-61.
10. Chinthaginjala H, Ahad HA, Srinivasa SK, Yaparla SR, Buddadasari S, Hassan JA, et al. Central Composite Design Assisted Formulation Development and Optimization of Gastroretentive Floating Tablets of Dextromethorphan Hydrobromide. Ind J Pharm Edu Res 2023;57:983-92.
11. Ahad HA, Chinthaginjala H, Priyanka MS, Raghav DR, Gowthami M, Jyothi VN. Datura stramonium Leaves Mucilage Aided Buccoadhesive Films of Aceclofenac using 3^2 Factorial Design with Design-Expert Software. Indian Journal of Pharmaceutical Education & Research 2021;55.
12. Elkady OA, Tadros MI, El-Laithy HM. QbD approach for novel crosslinker-free ionotropic gelation of risedronate sodium–chitosan nebulizable microspheres: optimization and characterization. AAPS PharmSciTech 2020;21:1-18.
13. Komati S, Swain S, Rao MEB, Jena BR, Unnam S, Dasi V. QbD-based design and characterization of mucoadhesive microspheres of quetiapine fumarate with improved oral bioavailability and brain biodistribution potential. Bulletin of Faculty of Pharmacy, Cairo University 2018;56:129-45.

14. Siraskar PR, Mishra DK. In-vivo estimation of optimized floating microspheres design by QBD approach. Research Journal of Pharmacy and Technology 2023;16:3697-700.
15. Shanmugasundaram S. QBD Approach for Design and Characterization of Pramlintide Microspheres for Controlled Drug Release. Journal of Pharmaceutical Innovation 2023;18:2325-47.
16. Bhavani J, Saloni S, Rajeshri D. Formulation and evaluation of floating microspheres using factorial design. Int J Recent Sci Res 2019;10:36363-70.
17. Abedullahh MH. Box-behnken design for development and optimization of acetazolamide microspheres. India 2014;5:1228-39.
18. Kyada C, Ranch K, Shah D. Optimization of mucoadhesive microspheres of acyclovir by applying 32 full factorial design. ratio 2014;1:B2.
19. Shinde ML, Shah VA, Ghodke DS, Shah RR. Impact of formulation and process variable on the preparation of acyclovir microspheres by spray drying using factorial design. Polymer 2010;3:5.
20. Hardenia A, Gupta AK. Development and optimization of gastroretentive mucoadhesive microspheres using 3^2 factorial design. International Journal of Pharmaceutical Sciences and Research 2016;7:2020.
21. Patel P, Dhake A. Design and development of colon specific microspheres for chronotherapy of hypertension. Journal of Pharmacy and Bioallied Sciences 2012;4:S33-S4.
22. Pande A, Nimbalkar U, Dhoka M, Sonawane P. Floating Microspheres of Cefpodoxime Proxitel: Formilation and Optimization by Factorial Design. IJRPC 2011;1:222-9.
23. Rai S, Ravikumar P. Development and evaluation of microsphere based topical formulation using design of experiments. Indian Journal of Pharmaceutical Sciences 2016;78:182-92.
24. Shazly GA, Tawfeek HM, Ibrahim MA, Auda SH, El-Mahdy M. Formulation and evaluation of fast dissolving tablets containing taste-masked microspheres of diclofenac sodium for sustained release. Digest Journal of Nanomaterials & Biostructures (DJNB) 2013;8.
25. Panwar MMS. Factorial design approach for optimization of floating microspheres of diltiazem hydrochloride. Asian Journal of Pharmaceutics (AJP) 2015:206-12.
26. Thombre NA, Shaikh HA, Ahire ED. Formulation Development and Evaluation of Colonspecific Esomeprazole Microspheres. Biosciences Biotechnology Research Asia 2022;19:679-91.
27. Nagpal M, Maheshwari D, Rakha P, Dureja H, Goyal S, Dhingra G. Formulation development and evaluation of alginate microspheres of ibuprofen. Journal of Young Pharmacists 2012;4:13-6.
28. Firke SN, Siraskar PR, Nagore DH, Ghiware NB. Formulation and Optimization of Floating Microspheres of Ivabradine Hydrochloride by 32 Factorial Design Approach.
29. Patel KS, Patel MB. Preparation and evaluation of chitosan microspheres containing nicorandil. International journal of pharmaceutical investigation 2014;4:32.
30. Lal C, Garg R, Gupta G. Formulation and optimization by applying 32 full factorial design of mucoadhesive microspheres of nifedipine. Asian J Pharm Clin Res 2019;12:321-7.
31. Dahiya T, Yadav S, Yadav N, Mann A, Sharma M, Rana J. Monitoring of BNP cardiac biomarker with major emphasis on biosensing methods: a review. Sensors International 2021;2:100103.

32. Bhopte DK, Sagar R, Kori ML. Fabrication, Optimization and Characterization of Floating Microspheres of Quinapril Hydrochloride using Factorial Design Method. Biomedical and Pharmacology Journal 2022;15:2011-24.
33. Prasanthi R, Haarika B, Selvamuthukumar S. Design Formulation and Statistical Evaluation of Gastroretentive Microspheres of Rasagiline Mesylate for Parkinson's Disease Using Design Expert. Ind J Pharm Edu Res 2023;57:s262-s73.
34. Prasanthi R, Haarika B, Selvamuthukumar S. Design Formulation and in vitro Evaluation of Gastroretentive Microspheres of Selegiline Hydrochloride for Parkinson's Disease by Design Expert. Ind J Pharm Edu Res 2024;58:s289-s97.
35. Dey S, Pramanik S, Malgope A. Formulation and optimization of sustained release stavudine microspheres using response surface methodology. International Scholarly Research Notices 2011;2011.
36. Mahaparale P, Nikam S, Chavan M. Development and Evaluation of Terbinafine Hydrochloride Polymeric Microsponges for Topical Drug Delivery. Indian Journal of Pharmaceutical Sciences 2018;80.